The long-term trend of the EPS is a vital number as it helps understand the future potential of PLx Pharma. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 21.30 % over the last twelve months. The long-term trend in EPS shows how well the management of PLx Pharma is adding value for shareholders.



PLx Pharma is part of the healthcare sector and is in the biotechnology industry. The company CEO is Natasha Giordano. PLx Pharma Inc is a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard delivery system to provide safer and more effective aspirin products.

Previous Intraday Performance:

The PLXP shares had a previous change of 1.37% which opened at 3.65 and closed at 3.70. It moved to an intraday high of 3.80 and a low of 3.61.

SeekingAlpha:  PLx Pharma down 9%

Historical Performance:

Over the last five trading days, PLXP shares returned 2.78% and in the past 30 trading days it returned -11.38%. Over three months, it changed -0.01%. In one year it has changed -43.08% and within that year its 52-week high was 7.60 and its 52-week low was 3.05. PLXP stock is 21.31% above its 52 Week Low.

Our calculations result in a 200 day moving average of 4.43 and a 50 day moving average of 3.82. Right now, PLXP stock is trading -16.39% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  PLx Pharma down 9%

Liquidity:

The company has a market cap of $32.3m with 8.7m shares outstanding and a float of 4.3m shares. Trading volume was 2,802 shares and has experienced an average volume of 4,088 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for PLx Pharma was -2.16 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.39.

Below was the last reported quarterly earnings per share:
06-30-2018:  -0.30
03-31-2018:  -0.40
12-31-2017:  -0.48
09-30-2017:  -0.44



Indicators Also to Watch:

Based on the latest filings, there is 2.80% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 1.27

SeekingAlpha:  RTI Surgical beats by $0.02, beats on revenue

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -95.42%, return on assets is -37.22%, price-to-sales is 54.10 and price-to-book is 4.86.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here